The Clinical Research Unit (CRU) has five primary responsibilities: clinical research quality assurance; clinical research education; clinical research informatics; clinical research analytics; and inter-institutional clinical research operations coordination. The Unit helps ensure appropriate coordination, communication and consistency throughout the clinical trials platform by managing or participating in all DF/HCC clinical trials activities. The CRU works closely with DF/HCC's protocol review office, which supports the PRMS, and other DF/HCC clinical trials cores, such as Research Pharmacy and Biostatistics. It also works with the clinical trials offices at member institutions to facilitate coordination, communication, standardization of processes and implementation of best practices. This critical clinical trials support core is administratively led by the Associate Director for Administration, Beverly Ginsburg-Cooper, who has overall responsibility for clinical trials operations and Jeffrey Clark, an experienced clinical investigator who provides faculty leadership to DF/HCC's extensive clinical trials efforts. Faculty Director: Jeffrey Clark, MD(MGH) Category: 4.02 (Clinical Trials Protocol Management & Data Management) Management: Cancer Center Managed

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-50
Application #
8790998
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2015-11-30
Budget Start
2014-12-01
Budget End
2015-11-30
Support Year
50
Fiscal Year
2015
Total Cost
$555,006
Indirect Cost
$62,960
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25
Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233
Kamareddine, Layla; Wong, Adam C N; Vanhove, Audrey S et al. (2018) Activation of Vibrio cholerae quorum sensing promotes survival of an arthropod host. Nat Microbiol 3:243-252
Schilit, Samantha L P; Morton, Cynthia C (2018) 3C-PCR: a novel proximity ligation-based approach to phase chromosomal rearrangement breakpoints with distal allelic variants. Hum Genet 137:55-62
Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Yao, Lina; Seaton, Sarah Craven; Ndousse-Fetter, Sula et al. (2018) A selective gut bacterial bile salt hydrolase alters host metabolism. Elife 7:
Jalbut, Marla M; Brunner, Andrew M; Amrein, Philip C et al. (2018) Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma 59:988-991
Tapela, Neo M; Peluso, Michael J; Kohler, Racquel E et al. (2018) A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. Front Oncol 8:187
Roemer, Margaretha G M; Redd, Robert A; Cader, Fathima Zumla et al. (2018) Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950

Showing the most recent 10 out of 411 publications